Fred E. Cohen - 26 Jul 2023 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Reporting relationship: Director
Issuer ticker: URGN
Reported as of: 26 Jul 2023
Net transaction value: +$661,494
SEC form: 4
Accepted by SEC: 28 Jul 2023, 18:06:09 UTC
Prior SEC filing: 21 Jun 2023
Next SEC filing: 08 Sep 2023
Source filing: View source filing
Reporting owner signature: /s/ Jason Smith, Attorney-in-Fact

Key filing fact

Fred E. Cohen filed Form 4 for UroGen Pharma Ltd. (URGN) on 28 Jul 2023.

Key facts

This page summarizes Fred E. Cohen's Form 4 filing for UroGen Pharma Ltd. (URGN).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 28 Jul 2023, 18:06.

Change

Previous filing in this sequence was filed on 21 Jun 2023.
Current net transaction value: +$661,494.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

URGN transaction

Ordinary Shares

Award

Transaction value: $661,494
Shares: +69,339
Change %
Price: $9.54
Shares after: 69,339
Date: 26 Jul 2023
Ownership: by Monograph Capital Partners, for which the reporting person is Chair and Chief Investment Officer
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents the reporting person's proportionate interest in shares acquired by entities affiliated with Monograph Capital Partners, for which the reporting person is Chair and Chief Investment Officer